Medicare spending higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment
MONDAY, June 13, 2022 (HealthDay News) — A diagnosis of Alzheimer disease or related dementia (ADRD) is associated with a large increase in Medicare spending, according to a study published online May 18 in the Journal of the American Geriatrics Society.
Geoffrey J. Hoffman, Ph.D., from the University of Michigan in Ann Arbor, and colleagues used the 1998 to 2018 Health and Retirement Study with linked Medicare claims to assess incremental quarterly spending changes just before versus just after a clinical dementia diagnosis (diagnosis cohort, 2,779) and among 2,318 individuals screened as impaired based on the validated Telephone Interview for Cognitive Status (impairment cohort).
The researchers found that overall spending was $4,773 per quarter, of which 43 percent was spending on hospital care ($2,048). Spending increased by 156 percent, from $5,394 in the quarter prior to diagnosis versus $13,794 in the quarter including the diagnosis. For the group with impairment, adjusted spending did not change from just before to after detection ($2,986 before and $2,962 after). There were no differences observed in incremental spending changes by sex, race, education, dual eligibility, or geography.
“Large, transient spending increases accompany an ADRD diagnosis that may not be attributed to impairment or changes in functional status due to dementia,” the authors write.
Insomnia Linked to Increased Risk for Stroke, Odds of Admission
Increased Dementia Risk Seen After Transient Ischemic Attack
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia
Voice Disorders Linked to Elevated Risk for Incident Cognitive Decline
Dementia, Stroke Risk Elevated for Those With Severe Mental Illness
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Exercise Link to Dementia Varies by Physical Activity Domain
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy